QDIS Blog

This came across my desk last week and I haven’t had time to comment on it yet. Seems Schering-Plough is interested in merging with Bristol-Myers Squibb.

Schering-Plough eyes Bristol-Myers deal: newspaper - washingtonpost.com:

I think this is just speculations on the part of major media, fueled the recent problems that BMS has had and with their CEO being fired. Knowing some of each company (I use to work for BMS) I think the culture and approach to drug development are so different that it would be difficult at best. While there appears to be a good match in terms of not having a lot of overlap in terms of promising areas, I feel these are overwhelmed by the differences in approaches to developing drugs.

I should point out that this seems to only have been discussed internally inside Schering-Plough and that they have not approached Bristol-Myers Squibb.

A lot will depend on the search for a new CEO at BMS and how whomever they hire views such a proposal. I’ll definitely keep my eye on this and see what develops in the near future.

Technorati Tags: BMS, Bristol-Myers Squibb, drug development, pharma M&A, pharmaceutical companies, Schering-Plough

Email Ed Vawter

Bookmark it with: | del.icio.us | Digg it | Furl | Simpy | Spurl | My Yahoo! |